Top Midday Decliners

MT Newswires Live03-31

Viridian Therapeutics (VRDN) on Monday reported "positive" topline data from the elegrobart REVEAL-1 phase 3 clinical trial in patients with active thyroid eye disease.

Wedbush said the study met its primary endpoint but raised questions on competitive profile. Wedbush cut its price target to $37 from $44 while maintaining its outperform rating.

Shares sank 32%, with an intraday trading volume of over 10.6 million against a daily average of about 1.43 million.

Sysco (SYY) agreed to acquire Jetro Restaurant Depot in a cash-and-stock deal worth about $29.1 billion in enterprise value to enter the Cash & Carry channel.

Shares dropped about 14%, with an intraday trading volume of over 16.3 million, versus a daily average of roughly 3.8 million.

Price: 18.49, Change: -8.90, Percent Change: -32.49

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment